Deferiprone for transfusional iron overload and its roles in developing countries

Bibliography

• Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann NY Acad Sci 2010;1202:17-23
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004;14-34
   PubMedGoogle Scholar
• Weatherall DJ, Clegg JB. editors. The thalassaemia syndromes. 4th edition. Blackwell Science, Oxford; 2001
   Google Scholar
• Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 2012;26(Suppl 1):S3-6
   PubMed Web of Science ®Google Scholar
• Taher AT, Viprakasit V, Musallam KM, et al. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol 2013;88:409-15
   PubMed Web of Science ®Google Scholar
• Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52
   PubMed Web of Science ®Google Scholar
• Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol 2002;76:219-28
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-87
   PubMed Web of Science ®Google Scholar
• Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med 2011;2:135-49
   PubMedGoogle Scholar
• Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001;79:704-12
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009;90:435-45
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Gattermann N, Lee JW, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus 2013;11:108-22
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62
   PubMed Web of Science ®Google Scholar
• Kusuwan T, Pangnukroh L, Leekamnerdthai W, et al. editors. Analysis of treatment complicance and related health and social determining factors in thai thalassemia patients under long-term deferrioxamine administration. Presented at the 13th National Thalassemia Conference; 4 – 5 October 2007; Miracle Grand Hotel, Bangkok, Thailand
   Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602
   PubMed Web of Science ®Google Scholar
• Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol 2012;8:123-34
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;118:884-93
   PubMed Web of Science ®Google Scholar
• Wood JC, Glynos T, Thompson A, et al. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol 2010;85:818-19
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica 2012;97:842-8
   PubMed Web of Science ®Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107:3436-41
   PubMed Web of Science ®Google Scholar
• Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 2011;96:521-5
   PubMed Web of Science ®Google Scholar
• Neufeld EJ, Galanello R, Viprakasit V, et al. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 2012;119:3263-8
   PubMed Web of Science ®Google Scholar
• Hider RC, Kontoghiorghes G, Silver J, et al. G. B. Patent 198498921; 1984
   Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 1987;295:1509-12
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Farmaki K, Carson S, et al. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 2012;3:119-29
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic effects of the lipophilic iron chelator omadine. FEBS Lett 1986;204:208-12
   PubMed Web of Science ®Google Scholar
• Taylor PD, Morrison IE, Hider RC. Microcomputer application of non-linear regression analysis to metal-ligand equilibria. Talanta 1988;35:507-12
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol Lett 1995;80:1-18
   PubMed Web of Science ®Google Scholar
• Singh S, Hider RC. Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl-radical-generating ability of various iron complexes. Anal Biochem 1988;171:47-54
   PubMed Web of Science ®Google Scholar
• Matsui D, Klein J, Hermann C, et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991;50:294-8
   PubMed Web of Science ®Google Scholar
• al-Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995;89:403-8
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990;48:255-61
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990;76:295-300
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-9
   PubMed Web of Science ®Google Scholar
• Morales NP, Yamanont P, Jirasomprasert T, et al. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int J Clin Pharmacol Ther 2009;47:358-64
   PubMed Web of Science ®Google Scholar
• Benoit-Biancamano MO, Connelly J, Villeneuve L, et al. Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos 2009;37:322-9
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741-8
   PubMed Web of Science ®Google Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-4
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Cossu G, Balocco M, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011;96:1708-11
   PubMed Web of Science ®Google Scholar
• Pratini NR, Sweeters N, Vichinsky E, et al. Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. Am J Phys Med Rehabil 2013;92:728-33
   PubMed Web of Science ®Google Scholar
• Kakhlon O, Breuer W, Munnich A, et al. Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol 2010;88:187-96
   PubMed Web of Science ®Google Scholar
• Gale GR, Litchenberg WH, Smith AB, et al. Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice. Res Commun Chem Pathol Pharmacol 1991;73:299-313
   PubMedGoogle Scholar
• Bergeron RJ, Streiff RR, Wiegand J, et al. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 1992;79:1882-90
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE((R))) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol 2013;88:251-60
   PubMed Web of Science ®Google Scholar
• Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev 2009;23(Suppl 1):S3-7
   Google Scholar
• Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000;85:115-17
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;80:593-9
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, AL-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;108:305-12
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007;92:1599-606
   PubMed Web of Science ®Google Scholar
• Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001;67:30-4
   PubMed Web of Science ®Google Scholar
• Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006;30:263-74
   PubMed Web of Science ®Google Scholar
• Peng CT, Wu KH, Wu SF, et al. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. Hemoglobin 2006;30:125-30
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerg Drugs 2006;11:1-5
   PubMedGoogle Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013;128(3):281-308
   PubMed Web of Science ®Google Scholar
• Christoforidis A, Haritandi A, Tsatra I, et al. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. Eur J Haematol 2007;78:52-7
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84
   PubMed Web of Science ®Google Scholar
• Mirbehbahani N, Jahazi A, Rahim Abad HH. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Hematology (Am Soc Hematol Educ Program) 2012;17:183-6
   Google Scholar
• Maggio A, Vitrano A, Lucania G, et al. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. Am J Hematol 2012;87:732-3
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011;96:41-7
   PubMed Web of Science ®Google Scholar
• Filosa A, Vitrano A, Rigano P, et al. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. Blood Cells Mol Dis 2013;51:85-8
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson 2013;15:1
   PubMed Web of Science ®Google Scholar
• Taher A, Aoun E, Sharara AI, et al. Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematol 2004;112:179-83
   PubMed Web of Science ®Google Scholar
• Jamuar SS, Lai AH, Tan AM, et al. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. J Paediatr Child Health 2011;47:812-17
   PubMed Web of Science ®Google Scholar
• Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol 2005;74:217-20
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7
   PubMed Web of Science ®Google Scholar
• Sheikh-Taha M, Koussa S, Taher A. Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient. Haematologica 2006;91:ECR25
   PubMedGoogle Scholar
• Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet 1989;2:457
   PubMed Web of Science ®Google Scholar
• Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations. Br J Haematol 1990;76:301-4
   PubMedGoogle Scholar
• Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007;109:5157-9
   PubMed Web of Science ®Google Scholar
• Clinton C, Gazda HT. Diamond-Blackfan Anemia. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors, GeneReviews™ [Internet] Seattle (WA). University of Washington, Seattle; 1993-2014. 2009 [updated 2014 Jan 16].
   Google Scholar
• Cermak J, Jonasova A, Vondrakova J, et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011;35:217-27
   PubMed Web of Science ®Google Scholar
• Choudhry VP, Pati HP, Saxena A, et al. Deferiprone, efficacy and safety. Indian J Pediatr 2004;71:213-16
   PubMedGoogle Scholar
• Hoffbrand AV. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005;18:299-317
   PubMed Web of Science ®Google Scholar
• Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-6
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-9
   PubMed Web of Science ®Google Scholar
• Vlachaki E, Tselios K, Perifanis V, et al. Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature. Clin Rheumatol 2008;27:1459-61
   PubMed Web of Science ®Google Scholar
• Mallat NS, Beydoun A, Musallam KM, et al. Deferiprone-induced seizures in a patient with beta-thalassemia major. Blood Cells Mol Dis 2013;51:94-5
   PubMed Web of Science ®Google Scholar
• Traynor K. Deferiprone approved for iron overload. Am J Health Syst Pharm 2011;68:2106
   Web of Science ®Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013;128:281-308
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:741-52
   PubMed Web of Science ®Google Scholar
• Ho PJ, Tay L, Lindeman R, et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J 2011;41:516-24
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Eleftheriou A, et al. Chapter 3: iron overload. In: Cappellini MD, Cohen A, Eleftheriou A, et al., editors, Guidelines for the clinical management of thalassemia. Thalassemia International Federation, Nicosia, Cyprus; 2007. p. 31-63
   Google Scholar
• Piga A, Longo F, Musallam KM, et al. Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the Italian Webthal project. Br J Haematol 2013;161:872-83
   PubMed Web of Science ®Google Scholar
• Luangasanatip N, Chaiyakunapruk N, Upakdee N, et al. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig 2011;31:493-505
   PubMed Web of Science ®Google Scholar